Questo è quello che abbiamo trovato per te
Si prevede che il numero di casi nel 2024 supererà i numeri già elevati dello scorso anno, mentre cresce la preoccupazione che la forma più grave e potenzialmente mortale continuerà a diffondersi. C’è il rischio di una nuova pandemia?
Oncologi, nuove cure e esami specifici migliorano sopravvivenza
Current test performance characteristics of blood-based colorectal cancer screening tests are insufficient to justify their high costs compared with less expensive and more effective alternatives such as fecal immunochemical testing, triennial stool DNA testing combined with a fecal immunochemical testing assay, and colonoscopy.
Results from a model involving 48 proteins and 43 metabolites as well as age, sex, and systolic blood pressure might indicate that a person is at increased risk for a myocardial infarction, or heart attack, within the next 6 months, according to a cohort study involving more than 2000 people in Europe. The ability to forecast someone’s short-term risk “may enhance the motivation of patients and doctors for primary prevention,” the researchers reported in Nature Cardiovascular Research.
New England, prove da uno studio su 8000 individui
Balzanelli, sperimentazione con assistenza tecnologica di Caltec
New England Journal of Medicine, Ahead of Print.
Vaia, ‘da noi nessun allarme ma potenziamo le azioni di vigilanza’
Performance of the new version was examined in 20,000 people who were undergoing screening colonoscopy.
This test detected 88% of early-stage colorectal cancers but sensitivity for advanced precancerous lesions was low.
New England Journal of Medicine, Volume 390, Issue 11, Page 973-983, March 2024.
New England Journal of Medicine, Volume 390, Issue 11, Page 984-993, March 2024.
Researchers have begun studying how accurately a new tool, known as the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator, estimates risk in people from different racial and ethnic backgrounds as well as from a range of ages, the American Heart Association announced. Three research teams will evaluate the new scores using larger databases and will assess PREVENT’s fairness and cost-effectiveness compared with the Pooled Cohort Equations (PCEs).
Una nuova circolare a quasi un mese dalla prima diffusa dalla direzione della Prevenzione del ministero della Salute
Aims
The aim was to evaluate whether standardised exercise performance during the incremental shuttle walk test (ISWT) can be used to assess disease severity in children and young people (CYP) with chronic conditions, through (1) identifying the most appropriate paediatric normative reference equation for the ISWT, (2) assessing how well CYP with haemophilia and cystic fibrosis (CF) perform against the values predicted by the best fit reference equation and (3) evaluating the association between standardised ISWT performance and disease severity.
Methods
A cross-sectional analysis was carried out using existing data from two independent studies (2018–2019) at paediatric hospitals in London,UK. CYP with haemophilia (n=35) and CF (n=134) aged 5–18 years were included. Published reference equations for standardising ISWT were evaluated through a comparison of populations, and Bland-Altman analysis was used to assess the level of agreement between distances predicted by each equation. Associations between ISWT and disease severity were assessed with linear regression.
Results
Three relevant reference equations were identified for the ISWT that standardised performance based on age, sex and body mass index (Vardhan, Lanza, Pinho). A systematic proportional bias of standardised ISWT was observed in all equations, most pronounced with Vardhan and Lanza; the male Pinho equation was identified as most appropriate. On average, CYP with CF and haemophilia performed worse than predicted by the Pihno equation, although the range was wide. Standardised ISWT, and not ISWT distance alone, was significantly associated with forced expiratory volume in 1 s in CYP with CF. Standardised ISWT in CYP with haemophilia was slightly associated with haemophilia joint health score, but this was not significant.
Conclusions
ISWT performance may be useful in a clinic to identify those with worsening disease, but only when performance is standardised against a healthy reference population. The development of validated global reference equations is necessary for more robust assessment.
Sesti (Simi), ‘intercetta precocemente i soggetti a rischio. Cure più tempestive’
